Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)

Summary

This is a pilot safety study of the oral PD-L1 inhibitor INCB099280 in patients with HCC awaiting liver transplant.

Timeline

Start

2024-05-01

Primary completion

2027-05-01

Completion

2028-09-01

Outcome

Outcome not reported

Stopped (Enrollment): “Incyte made a strategic business decision to stop enrollment to all ongoing oral PD-L1 (99280) studies. This decision was made based on an internal review and reprioritization of the existing pipeline.”

Drugs

Indications